Trial Profile
A Phase II Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Methylprednisolone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 11 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Aug 2010 New trial record